What types of topical knee gels are available for managing knee pain and how should they be applied?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Types of Knee Gels for Managing Knee Pain

Topical NSAIDs, specifically diclofenac gel, are the primary topical knee gel recommended for knee osteoarthritis, with strong evidence supporting their efficacy and safety. 1, 2

Primary Recommendation: Topical NSAID Gels

Topical diclofenac gel (1% concentration) is strongly recommended as first-line topical therapy for knee pain from osteoarthritis. 1, 3 This formulation demonstrates:

  • Significant pain reduction (effect size 0.91 compared to placebo) 4
  • Improved physical function over 8-12 weeks 5
  • Superior safety profile compared to oral NSAIDs, particularly in patients ≥75 years 2
  • Low systemic absorption minimizing gastrointestinal, cardiovascular, and renal risks 3

Application Protocol for Topical Diclofenac:

  • Apply 4 grams to the affected knee
  • Four times daily dosing
  • Rub into skin until absorbed
  • Total daily dose: 16 grams (320 mg diclofenac) 5, 6

The 2019 ACR/Arthritis Foundation guidelines provide the strongest recommendation, stating topical NSAIDs should be considered before oral NSAIDs due to their favorable risk-benefit profile 1. This is particularly critical for elderly patients where the strong recommendation specifies topical over oral formulations 2.

Alternative Topical Formulations

Topical Diclofenac Solution and Patches

Beyond gel formulations, diclofenac is available as:

  • Solution: Sustained efficacy over 3-6 weeks 7
  • Patch: Most pronounced short-term pain relief at 1-2 weeks (SMD: -0.64) 7

All three formulations (gel, solution, patch) show comparable safety with low skin-related adverse events 7.

Topical Capsaicin

Conditionally recommended for knee OA only, with important caveats 1:

  • Small effect sizes with wide confidence intervals
  • Frequent local adverse effects (burning, stinging sensation) 3
  • Questionable blinding in trials due to these sensory effects 3
  • Conditionally recommended AGAINST for hand OA due to eye contamination risk 1

Application requires 3-4 times daily for several weeks before maximal benefit.

Menthol-Based Gels

Evidence is limited and conflicting 8:

  • Some within-group improvements in functional tasks
  • No significant between-group differences versus placebo
  • May provide subjective pain relief during specific activities
  • Not included in major guideline recommendations

Clinical Algorithm for Topical Knee Gel Selection

Step 1: Start with topical diclofenac 1% gel (4g four times daily)

  • Use for minimum 2-4 weeks to assess efficacy 5
  • Particularly appropriate for patients >75 years, those with GI/CV/renal risk factors, or taking multiple medications 2, 1

Step 2: If inadequate response after 4 weeks:

  • Consider switching to diclofenac patch for enhanced short-term relief 7
  • Or add (not substitute) oral NSAIDs if no contraindications 1

Step 3: If topical NSAIDs fail or are contraindicated:

  • Consider topical capsaicin (accept burning sensation as expected effect)
  • Counsel patient on 2-4 week onset of action

Step 4: If multiple joints affected or topical therapy insufficient:

  • Transition to oral NSAIDs with appropriate GI protection 1
  • Consider intra-articular corticosteroid injection for acute exacerbations with effusion 4, 1

Important Clinical Pitfalls

Common mistakes to avoid:

  1. Prescribing insufficient quantity: Patients need 4 grams per application, not a "thin layer" - this requires adequate tube sizes for compliance 5

  2. Premature discontinuation: Benefits accumulate over 4-12 weeks; assess efficacy only after adequate trial duration 7, 5

  3. Using topical NSAIDs for hip OA: Joint depth beneath skin makes topical penetration ineffective - this is not recommended 1

  4. Combining multiple topical NSAIDs: No evidence for additive benefit and may increase systemic absorption

  5. Ignoring application site dermatitis: Most common adverse effect (4.8% with diclofenac gel), though usually mild 5

Safety Considerations

Topical NSAIDs demonstrate excellent tolerability 5:

  • Application site dermatitis: 4.8% (usually mild)
  • No treatment-related GI adverse events in trials
  • No serious adverse events attributed to topical diclofenac
  • Systemic NSAID levels 5-15% of oral dosing 3

However, systemic absorption still occurs - maintain caution in patients with severe renal impairment, active peptic ulcer disease, or aspirin-sensitive asthma 1.

The evidence strongly supports topical diclofenac gel as the primary topical therapy for knee OA, with a clear hierarchical approach when initial therapy proves insufficient.

References

Related Questions

How should I apply topical diclofenac (1% gel/ointment) to treat pain in my right knee, including dosage, frequency, duration, contraindications, and precautions?
Is diclofenac appropriate for treating knee pain?
Are topical agents effective for localized pain relief?
Is Biofreeze (menthol) safe and appropriate for managing chronic knee pain in adults?
How should Biofreeze (topical menthol 4% gel/cream) be prescribed for a nursing‑home resident with knee osteoarthritis?
In a patient with bipolar depression who has previously tolerated venlafaxine (Effexor), is it appropriate to start desvenlafaxine (Effexor) as treatment?
How should cariprazine (Vraylar) be initiated and dosed for bipolar I depression, considering prior venlafaxine use and any existing mood stabilizers?
What is the recommended treatment for seborrheic dermatitis presenting as a dry, itchy, erythematous facial rash with white flaky scales in a patient with uncontrolled diabetes?
Should a patient taking desvenlafaxine (Pristiq) extended‑release 50 mg discontinue it and begin cariprazine (Vraylar)?
What are the common causes, presenting symptoms, and recommended management for mechanical low back pain in a Canadian OSCE setting?
A patient in an assisted living facility with a history of insulin use presents with blood glucose levels of 426 mg/dL, then 385 mg/dL after one hour, and 365 mg/dL after another hour, and is currently not on any antidiabetic medication. How should this severe hyperglycemia be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.